Human medicines European public assessment report (EPAR): Refixia, nonacog beta pegol, Date of authorisation: 02/06/2017, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Refixia, nonacog beta pegol, Date of authorisation: 02/06/2017, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Xtandi, enzalutamide, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Xtandi, enzalutamide, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 27, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Vaxxitek HVT+IBD+H5, avian influenza vaccine (live recombinant), Status: Authorised

Veterinary medicines European public assessment report (EPAR): Vaxxitek HVT+IBD+H5, avian influenza vaccine (live recombinant), Status: Authorised

EMA workshop on the challenges in drug development, regulation and clinical practice for immunoglobulins, Online, European Medicines Agency, Amsterdam, the Netherlands, from 5 March 2025, 14:00 (CET) to 5 March 2025, 18:00 (CET)

EMA workshop on the challenges in drug development, regulation and clinical practice for immunoglobulins, Online, European Medicines Agency, Amsterdam, the Netherlands, from 5 March 2025, 14:00 (CET) to 5 March 2025, 18:00 (CET)

Cancer Medicines Forum: September 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 4 September 2025, 14:00 (CEST) to 4 September 2025, 17:00 (CEST)

Cancer Medicines Forum: September 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 4 September 2025, 14:00 (CEST) to 4 September 2025, 17:00 (CEST)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.